Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option

Sevabertinib offers a new targeted treatment option in China for adults with advanced or metastatic non-squamous NSCLC harboring activating HER2 mutations after prior systemic therapy.

Top Stories

Latest Coverage

From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding
From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding
Where Pancreatic Cancer Develops Matters: Understanding Pancreatic Head Cancer vs. Body and Tail Cancer
Pancreatic cancer is a malignant tumor that develops in the pancreas. While many people know that pancreatic cancer c...
New Progress in First-Line Treatment of HER2-Positive Breast Cancer: Trastuzumab Deruxtecan Plus Pertuzumab Approved
On August 12, 2026, Daiichi Sankyo announced that trastuzumab deruxtecan (T-DXd, brand name: Enhertu), a HER2-targete...
Which Pancreatic Cancer Patients May Benefit from Immunotherapy? An Analysis of Biomarkers and Treatment Options
Pancreatic cancer is one of the common malignant tumors of the digestive system, with pancreatic ductal adenocarcinom...
Colorectal Cancer Immunotherapy: How MSI-H/dMMR Helps Identify Patients Who May Benefit
The treatment landscape for colorectal cancer is changing rapidly. With advances in precision medicine, treatment dec...
What Are the Targeted Therapy Drugs for Liver Cancer? Common Targeted Drugs and Treatment Options
Liver cancer is one of the most common malignant tumors worldwide. Among them, hepatocellular carcinoma (HCC) is the ...

In-Depth Analysis


This site uses Just the Docs, a documentation theme for Jekyll.